Alkermes Initiates Phase 2 Study of Orexin Receptor Agent ALKS 2680 in Narcolepsy Type 2

Published Date: 29 Aug 2024

Vibrance-2 is a double-blind, placebo-controlled trial with 80 participants, assessing three doses of ALKS 2680 over eight weeks

Read Full News

Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Sub-Q Ketamine is Safe and Very Effective for Severe Depression.

2.

Study indicates that exercise can help colon cancer survivors live as long as matched individuals

3.

Contradictory Results Are Found in Two Pembrolizumab Trials for Head and Neck Cancer.

4.

Can Concurrent Boost Safely Shorten Breast Cancer Radiation?

5.

Positive Trials; Malignancies Increasing in Younger Adults; Andre Braugher's Cancer Dx.


© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot